We currently recommend the incorporation of FLT3i’s and ASCT in CR1 in all ASCT eligible patients with a FLT3-ITDmut AML, irrespective of the AR and/or NPM1 co-mutation status. The gene discussed is FLT3; the disease is acute myeloid leukemia.